Patents Issued in April 16, 2020
  • Publication number: 20200115362
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20200115363
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, E, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 16, 2020
    Inventors: Liansheng LI, Jun FENG, Tao WU, Yuan LIU, Yi WANG, Pingda REN, Yi LIU
  • Publication number: 20200115364
    Abstract: The present disclosure relates in parts to compounds capable of emitting delayed fluorescence and uses of these compounds in organic light-emitting diodes.
    Type: Application
    Filed: June 25, 2018
    Publication date: April 16, 2020
    Inventors: Jorge AGUILERA-IPARRAGUIRRE, Rafael GOMEZ-BOMBARELLI, Timothy D HIRZEL, Yoshitake SUZUKI, Shuo-Hsien CHENG, Yu Seok YANG, Naoto NOTSUKA, Ayataka ENDO, Keiro NASU, Tsang Ping KUEN
  • Publication number: 20200115365
    Abstract: The present invention discloses novel indolylkojyl compounds of formula 1 The invention also provides a one pot, green chemistry method for preparation of indolylkojyl com-pounds. The compounds of the present invention are selectively toxic towards human breast cancer cells and inhibit tumor growth as well as lung metastasis. The compounds also potentiate the effect of anticancer drugs.
    Type: Application
    Filed: February 5, 2018
    Publication date: April 16, 2020
    Inventors: Debaraj MUKHERJEE, Anindya GOSWAMI, Deepak SHARMA, Debasis NAYAK, Shreyans Kumar JAIN
  • Publication number: 20200115366
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: February 15, 2019
    Publication date: April 16, 2020
    Inventors: Sara S. HADIDA RUAH, Peter D.J. GROOTENHUIS, Fredrick VAN GOOR, Jinglan Zhou, Brian BEAR, Mark T. MILLER, Jason McCARTNEY, Mehdi Michel Jamel NUMA, Xiaoqing YANG
  • Publication number: 20200115367
    Abstract: The instant invention provides compounds of formula I which are selective JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 16, 2020
    Applicant: Intervet Inc.
    Inventors: Peter H. Fuller, Jason Brubaker, Jonathan R. Young
  • Publication number: 20200115368
    Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
  • Publication number: 20200115369
    Abstract: The present invention discloses an indenotriphenylene-based amine derivative and an organic electroluminescence device employing the indenotriphenylene-based amine derivative as the dopant material, the hole transporting material, or the electron blocking material of the organic electroluminescence device. The organic electroluminescence device of the present invention exhibits improved performance, such as reduced power consumption, increased current efficiency, and longer half-life time.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 16, 2020
    Applicant: LUMINESCENCE TECHNOLOGY CORPORATION
    Inventors: FENG-WEN YEN, WEN-FENG HSIAO
  • Publication number: 20200115370
    Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 16, 2020
    Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor, III
  • Publication number: 20200115371
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: October 17, 2019
    Publication date: April 16, 2020
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Publication number: 20200115372
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 1, 2017
    Publication date: April 16, 2020
    Inventors: Russell C. Petter, James Gregory Barsoum
  • Publication number: 20200115373
    Abstract: A thermosetting oligomer is disclosed, comprising repeat units of the formula wherein Ar is a C6-32 arylene, preferably a C13-17 diarylene methylene; Ra and Rb at each occurrence are each independently a halogen, C1-12 alkyl, C2-12 alkenyl, C3-8 cycloalkyl, or C1-12 alkoxy, preferably a C1-3 alkyl; R3 at each occurrence is independently a halogen or a C1-6 alkyl group, preferably a C1-3 alkyl; R4 a C1-25 hydrocarbyl, preferably a C1-6 alkyl, a phenyl, or a phenyl substituted with up to five C1-6 alkyl groups, more preferably a C1-3 alkyl or a phenyl; and c, p and q at each occurrence are each independently 0 to 4.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 16, 2020
    Inventors: TARUN KUMAR PAL, PRAKASH SISTA, JAYKISOR PAL
  • Publication number: 20200115374
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 16, 2020
    Inventors: Martha Alicia DE LA ROSA, Wieslaw Mieczyslaw KAZMIERSKI, Vicente SAMANO
  • Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI
  • Publication number: 20200115376
    Abstract: The present disclosure relates to compounds capable of emitting delayed fluorescence, and uses of these compounds in organic light-emitting diodes.
    Type: Application
    Filed: June 25, 2018
    Publication date: April 16, 2020
    Inventors: Jorge AGUILERA-IPARRAGUIRRE, Rafael GOMEZ-BOMBARELLI, Timothy D HIRZEL, Naoto NOTSUKA, Yoshitake SUZUKI, Yu Seok YANG, Shuo-Hsien CHENG, Ayataka ENDO, Keiro NASU, Tsang Ping KUEN
  • Publication number: 20200115377
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventor: Gerald Horn
  • Publication number: 20200115378
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Publication number: 20200115379
    Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 16, 2020
    Inventors: Hongbin LIU, Yue RONG, Huajie ZHANG, Zhifang CHEN, Rui TAN, Chengxi HE, Zhifu LI, Zuwen ZHOU, Haohan TAN, Kai RAN, Xianlong WANG, Zongyao ZOU, Lihua JIANG, Yanxin LIU, Xingdong ZHAO, Weibo WANG, Jiemin FU
  • Publication number: 20200115380
    Abstract: The present invention provides methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: John Charles TOMESCH, Peng LI, Wei YAO, Qiang ZHANG, James David BEARD, Andrew S. THOMPSON, Hua CHENG, Lawrence P. WENNOGLE
  • Publication number: 20200115381
    Abstract: A dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also, use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.
    Type: Application
    Filed: June 25, 2018
    Publication date: April 16, 2020
    Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Qingyun REN, Xinchang LIU, Jianzhou HUANG, Yingjun ZHANG, Siegfried GOLDMANN
  • Publication number: 20200115382
    Abstract: Provided are a curable composition, a cured film, an optical filter, a solid image pickup element, an image display device, an infrared sensor, a dispersing auxiliary agent, a dispersion, and a method of manufacturing a dispersion. With the curable composition, a cured film having excellent moisture resistance in which the formation of an aggregate derived from a compound having a colorant skeleton is suppressed can be formed. This curable composition includes: a compound A having a structure in which at least one functional group selected from an acid group having a pKa of 3 or lower and a Clog P value of ?1.1 or higher, an anionic group obtained by dissociating one or more hydrogen atoms from the acid group, or a salt of the acid group is bonded to a ?-conjugated structure of a colorant skeleton and having a maximum absorption wavelength in a wavelength range of 650 to 1200 nm; a curable compound; and a solvent.
    Type: Application
    Filed: December 10, 2019
    Publication date: April 16, 2020
    Applicant: FUJIFILM Corporation
    Inventors: Takuya TSURUTA, Hiroaki TSUYAMA, Kyohei ARAYAMA, Suguru SAMEJIMA, Tokihiko MATSUMURA, Tetsushi MIYATA, Kazutaka TAKAHASHI
  • Publication number: 20200115383
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Steven DO, Tamiko KATSUMOTO, Jun LIANG, Naomi S. RAJAPAKSA, James Richard KIEFER, Jr., Liqiang FU
  • Publication number: 20200115384
    Abstract: The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 16, 2020
    Inventors: Frank Wu, Lin Li, Xiaoju Yang
  • Publication number: 20200115385
    Abstract: The invention relates to a crosslinking compound of formula (I) In particular, the present invention relates to a liquid composition comprising a monomer, a (meth)acrylic polymer and at least one crosslinking compound of formula (I). This liquid composition may be used in the form of a syrup and in particular in the form of a syrup for impregnating fibers or fibrous material. The invention also relates to a pseudo-thermoplastic material obtained after polymerization of the liquid composition being at least partially crosslinked. The invention also relates to a process for manufacturing such a liquid composition. The invention also relates to a process for impregnating a long-fiber fibrous substrate with said liquid composition. The invention also relates to a fibrous substrate impregnated with said liquid composition which is useful for manufacturing composite parts.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 16, 2020
    Inventors: Jean-Claude Fontanier, Jean-Francois GERARD, Peirre GERARD, Frederic LORTIE, Jean-Pierre PASCAULT
  • Publication number: 20200115386
    Abstract: The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.
    Type: Application
    Filed: March 2, 2017
    Publication date: April 16, 2020
    Applicant: Anhui New Star Pharmaceutical Development Co., Ltd .
    Inventors: Xianming Deng, Dawang Zhou, Lanfen Chen, Zhixiang He, Fuqin Fan
  • Publication number: 20200115387
    Abstract: The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions and formulations containing them, to the use of the compounds and compositions as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE devices comprising these compounds or compositions.
    Type: Application
    Filed: July 5, 2017
    Publication date: April 16, 2020
    Applicant: Merck Patent GmbH
    Inventors: William MITCHELL, Mansoor D'LAVARI, Changsheng WANG
  • Publication number: 20200115388
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, Naomi S. RAJAPAKSA, James Richard KIEFER, JR.
  • Publication number: 20200115389
    Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • Publication number: 20200115390
    Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 16, 2020
    Inventors: Philip Wilson Howard, Stephen John Gregson
  • Publication number: 20200115391
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Publication number: 20200115392
    Abstract: Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma.
    Type: Application
    Filed: February 28, 2018
    Publication date: April 16, 2020
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jian XIONG, Cheng XIE, Kevin X CHEN, Xiongbin XU, Xuejin ZHANG, Zhen GONG, Jian LI, Shuhui CHEN, Aiming ZHANG, Zhulian JIANG, Xiquan ZHANG, Xin TIAN
  • Publication number: 20200115393
    Abstract: A process for a continuous production of a boronic acid derivative and an apparatus of performing the process are disclosed.
    Type: Application
    Filed: January 31, 2018
    Publication date: April 16, 2020
    Inventors: Andreas PELZ, Christian SCHUSTER, Stefan STEINHOFER, Clemens STUECKLER, Maria VASILOIU, Christopher ZINGANELL
  • Publication number: 20200115394
    Abstract: A borated benzoxazine compound, which can be used in particular as monomer in the synthesis of polybenzoxazine, corresponds to the formula: in which: Z represents an at least divalent, aliphatic, cycloaliphatic or aromatic, bonding group comprising at least one carbon atom and optionally at least one heteroatom chosen from O, S and P; and R1, R2, R3 and R4, which are identical or different, represent hydrogen or an alkyl comprising from 1 to 12 carbon atoms, it being possible for R1 and R2, on the one hand, and R3 and R4, on the other hand, optionally to form a heterocycle with the two oxygen atoms and the boron atom to which they are respectively bonded.
    Type: Application
    Filed: May 28, 2018
    Publication date: April 16, 2020
    Inventors: MILAN FEDURCO, MARCO RIBEZZO
  • Publication number: 20200115395
    Abstract: The present invention relates to a method for preparing size-modulated UiO-66, which is achieved by modulating the concentrations of reactants, and a catalyst with improved activity of hydrolyzing chemical warfare agents prepared by the method.
    Type: Application
    Filed: April 26, 2019
    Publication date: April 16, 2020
    Inventors: Kyung Youl BAEK, Chong Min KOO, Soon Man HONG, Seung Sang HWANG, Sangho CHO, Jin Young SEO, Do Xuan HUY, Younghan SONG, Sejin KIM, Changju SUNG, Yeojin AHN
  • Publication number: 20200115396
    Abstract: The present disclosure describes methods for silylating heteroaromatic derivatives, comprising the use of hydrosilanes and potassium hydroxide.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 16, 2020
    Inventors: Anton Toutov, Kerry Betz, Alexey Fedorov, Brian M. Stoltz, Wenbo Liu, Robert H. Grubbs
  • Publication number: 20200115397
    Abstract: The process of bi-functionalizing silicon nanoparticles and bi-functionalized silicon nanoparticles are described. The processes include applying shear forces to silicon metal in the presence of an alkane, thereby providing an alkyl-hydride-functionalized silicon nanoparticle, which is then treated with a reactant, e.g., a compound that reacts with the hydride functionality, to provide the bi-functionalized silicon nanoparticles. The resulting product can include a plurality of functionalities on a silicon nanoparticle derived from alkenes, alkynes, aldehydes, alcohols, thiols, amines, carboxylates, and/or carboxylic acids.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 16, 2020
    Applicant: Nanostar Inc.
    Inventors: Shiva Adireddy, Alexander L. Girau, Jonathan Goodman, Sai Abhishek Palaparty, Meysam Shahami, Meet Amit Vora
  • Publication number: 20200115398
    Abstract: Macromolecules comprising triazoles and related compositions and methods are provided. In some embodiments, a macromolecule may comprise one or more repeat units including a triazole and a functionalizable pendant group. The macromolecule may also comprise one or more orthogonally addressable end groups. In some embodiments, one or more repeat units may be formed by a synthetic process that allows for precise control over stereochemistry, pendant functionality, and/or the spatial relationship (e.g., distance) between groups in the repeat unit(s). Such precise control over pendant group and repeat unit structure allows for the macromolecule functionality, stereochemistry, and spacing between groups (e.g., pendant groups) to be precisely controlled. Macromolecules described herein may be used for a wide variety of applications, including the delivery of active agents.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 16, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Jeremiah A. Johnson, Yoshiki Shibuya, Hung Vanthanh Nguyen, Yivan Jiang
  • Publication number: 20200115399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Publication number: 20200115400
    Abstract: The present invention provides a method for producing a silicon compound shown by the following general formula (3) through a hydrosilylation reaction between a hydrosilane compound shown by the following general formula (1) and a carbonyl group-containing alicyclic olefin compound shown by the following general formula (2), in which the hydrosilylation reaction takes place while an acidic compound or acidic compound precursor is gradually added in presence of a platinum-based catalyst. This provides a highly-efficient industrial method for producing an industrially useful, hydrolysable silicon compound having an alicyclic structure (particularly a norbornane ring) and a carbonyl group.
    Type: Application
    Filed: September 25, 2019
    Publication date: April 16, 2020
    Applicant: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Ryo MITSUI, Takeru WATANABE, Seiichiro TACHIBANA, Tsutomu OGIHARA
  • Publication number: 20200115401
    Abstract: To provide a method for producing a phosphoryl imide salt represented by the following general formula (1) at a satisfactory yield by cation exchange. The method comprises the step of performing cation exchange by bringing a phosphoryl imide salt represented by the following general formula (2) into contact with a cation exchange resin having M1 n+ or a metal salt represented by the general formula (4) in an organic solvent having a water content of 0.3% by mass or less.
    Type: Application
    Filed: April 9, 2018
    Publication date: April 16, 2020
    Applicant: CENTRAL GLASS CO., LTD.
    Inventors: Mikihiro TAKAHASHI, Takayoshi MORINAKA, Masutaka SHINMEN, Ryosuke TERADA
  • Publication number: 20200115402
    Abstract: The present invention refers to a process for the preparation of a mono(acyl)phosphine of the general formula (I) and/or a bis(acyl)phosphine of the general formula (II), wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylaryl-sulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NIIR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5-or 6-membered heterocyclic ring; R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation; Formula (II) wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently sele
    Type: Application
    Filed: May 30, 2018
    Publication date: April 16, 2020
    Inventors: Reinhard H. Sommerlade, Souad Boulmaaz
  • Publication number: 20200115403
    Abstract: The present invention refers to a process for the preparation of a bis(acyl)phosphinic acid silyl ester of the general formula (I), wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR12, NHR12 or NR12R13 with R12 and R13 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; R6 is OSiR14R15R16 with R14, R15 and R16 being independently selected from linear or branched C1-C20-alkyl or C6-C12-aryl; as well as the bis(acyl)phosphinic acid silyl ester and the bis(acyl)phosphinic acid obtained by the process.
    Type: Application
    Filed: June 27, 2018
    Publication date: April 16, 2020
    Inventors: Reinhard H. Sommerlade, Kai Uwe Luckner
  • Publication number: 20200115404
    Abstract: Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 16, 2020
    Inventors: Bin WANG, Hanbiao YANG, Karl BEDKE, Paul WEHN, James P. RIZZI
  • Publication number: 20200115405
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Publication number: 20200115406
    Abstract: An organometallic compound represented by Formula 1: wherein, in Formula 1, groups and variables are the same as described in the specification.
    Type: Application
    Filed: August 28, 2019
    Publication date: April 16, 2020
    Inventors: Jeoungin YI, Juhyun KIM, Sangho PARK, Sunyoung LEE, Seokhwan HONG, Kyuyoung HWANG, Yoonhyun KWAK, Sunghun LEE, Byoungki CHOI, Hyeonho CHOI
  • Publication number: 20200115407
    Abstract: The invention relates to the field of nutritional ingredients, in particular to methods for producing hypoallergenic galacto-oligosaccharides (GOS) and the use thereof in food and drink items. Provided is the use of a beta-galactosidase (EC 3.2.1.23) derived from Cryptococcus terrestris (recently renamed Papiliotrema terrestris) in the production of a hypoallergenic GOS preparation having a reduced capacity to induce an allergic response in a subject.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 16, 2020
    Inventors: Dirk Andries GROENEVELD, Bas Johan Henri KUIPERS, Bernardina Johanna Martina DELSING, Linqiu CAO
  • Publication number: 20200115408
    Abstract: Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 16, 2020
    Inventor: Benjamin M. Swarts
  • Publication number: 20200115409
    Abstract: The present specification relates to an anti-inflammatory composition including a novel compound isolated from a post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and may be widely used in various areas related to anti-inflammation.
    Type: Application
    Filed: June 11, 2018
    Publication date: April 16, 2020
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Yong-Deog HONG, Jeong-Kee KIM
  • Publication number: 20200115410
    Abstract: Provided is a compound of the general formula (1), which is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human, as well as a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 16, 2020
    Inventors: Hakon LEFFLER, Ulf NILSSON, Fredrik ZETTERBERG
  • Publication number: 20200115411
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Application
    Filed: May 10, 2019
    Publication date: April 16, 2020
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA